Found: 5
Select item for more details and to access through your institution.
iGlarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real‐world study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1249, doi. 10.1111/dom.14974
- By:
- Publication type:
- Article
Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 11, p. 2089, doi. 10.1111/dom.14127
- By:
- Publication type:
- Article
Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study.
- Published in:
- Diabetes Spectrum, 2023, v. 36, n. 3, p. 253, doi. 10.2337/ds22-0064
- By:
- Publication type:
- Article
The Clinical and Economic Impact of the V-Go Disposable Insulin Delivery Device for Insulin Delivery in Patients with Poorly Controlled Diabetes at High Risk.
- Published in:
- Drugs - Real World Outcomes, 2016, v. 3, n. 2, p. 191, doi. 10.1007/s40801-016-0075-4
- By:
- Publication type:
- Article
Use of V-Go Insulin Delivery Device in Patients with Sub-optimally Controlled Diabetes Mellitus: A Retrospective Analysis from a Large Specialized Diabetes System.
- Published in:
- Diabetes Therapy, 2015, v. 6, n. 4, p. 531, doi. 10.1007/s13300-015-0138-7
- By:
- Publication type:
- Article